跳至主要内容
临床试验/NCT03687853
NCT03687853Unknown不适用

Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver Metastases After Pancreatic Cancer Surgery

Peking University Third Hospital1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2017年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
80
试验地点
1
主要终点
Death

研究概览

简要总结

Clinical results on intra-arterial adjuvant chemotherapy for prevention

of liver metastasis following curative resection of pancreatic cancer

详细描述

In this study, the investigator try to select 80 patients who received radical surgery for pancreatic cancer, whose circulating tumor cells(CTCs) count then performed on intraoperative portal venous blood to predict postoperative liver metastasis and were divided into two groups. for those who have high CTCs count may have more chance for the occurrence of postoperative liver metastasis was applied hepatic arterial perfusion chemotherapy with minimal dynamic randomization. The aim is to evaluate the feasibility of hepatic arterial infusion chemotherapy for the prevention of postoperative liver metastasis and improvement of prognosis of pancreatic cancer, so as to further improve postoperative management of pancreatic cancer

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Participant)

盲法说明

Pancreatic cancer patients who received chemotherapy through peripheral vein after operation

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • pancreatic cancer patients who received the radical operation

排除标准

  • who accepted chemotherapy before operation or who cannot or do not will to accepted enrolled into this study

研究组 & 干预措施

Intrahepatic Arterial Infusion chemotherapy

Experimental

chemotherapy through intrahepatic arterial Infusion is one of the most widely used liver tumor treatments.

干预措施: Intrahepatic Arterial Infusion (Device)

control

No Intervention

chemotherapy through Peripheral venous is one of the regularly used method.

结局指标

主要结局

Death

时间窗: up to 12 months

Overall survival time after operation

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验